Business Wire

Applied Value Announces Growth Investment from Trivest Partners

22.8.2025 14:00:00 CEST | Business Wire | Press Release

Share

Applied Value Group (“Applied Value” or the “Company”), a premier management consulting firm specializing in advising and executing on cost and capital efficiency improvements for global Fortune 500 and private equity clients, today announced a growth investment from Trivest Partners (“Trivest”), a private equity firm focused on investing in founder-owned businesses with approximately $6 billion assets under management. Partnering with Trivest will allow Applied Value to accelerate its growth plans and further cement its position as a leading consultancy focused on rapidly realizing true bottom-line results for clients. Terms of the deal were not disclosed.

Since its founding in 1997, Applied Value has developed a reputation for providing best-in-class, results-driven consulting services focusing on gross margin expansion, fixed cost reduction, and working capital efficiency. The investment from Trivest is designed to significantly scale Applied Value’s offering, broaden its suite of capabilities for corporate and private equity clients, and expand its global reach with a focus on North America and the Nordics. Additionally, Applied Value will look to strategically pursue targeted add-on acquisitions and further attract and retain top industry talent.

As part of the new partnership, Applied Value Group’s remaining family office investments and social impact initiatives will be incorporated under Applied Invest LLC, while Applied Value Group will comprise the consultancy business. This structure will preserve the shared owner-operator DNA that has been pivotal to the Company’s success. Applied Value’s management team, including Chief Executive Officer Ryan Huff and founder and Executive Chairman Bruce Grant, will remain in place to help lead the business in its next phase of growth.

“After running both the Nordics and North America businesses at one of the world’s largest management consulting firms, I wanted to create something different. A firm that prioritized the execution of impactful solutions to create both immediate and lasting bottom-line results – thus creating Applied Value. Central to this is our owner-operator mindset that allows us to be pragmatic and entrepreneurial with our clients. I am excited to usher in the next chapter of Applied Value’s evolution through our partnership with Trivest. I believe with their support and capital, we can drive accelerated long-term growth while preserving the unique characteristics that have been foundational to our success so far,” said Bruce Grant, Founder & Executive Chairman at Applied Value Group.

“From our very first meeting, it was clear that the Trivest team shares a common entrepreneurial spirit and drive. Their focused approach working with founder-led businesses makes them a great fit for Applied Value. I look forward to working with Mario and the rest of the Trivest teamto continue to scale our business as well as pursue additional opportunities across the highly attractive private equity channel. We are confident that they are the right partner for us in this next stage of our evolution, and are excited to open up new opportunities for our valued current and future clients and exceptionally talented team,”said Ryan Huff, Chief Executive Officer at Applied Value Group.

“The professional services space is an increasingly compelling area for us at Trivest as the top business models align with our focus on partnership. Applied Value fits that mold and exhibits all the hallmarks we like to see when investing in a founder-owned business. We have been deeply impressed by Applied Value’s culture of excellence that Bruce, Ryan, and the team have built. We believe Applied Value’s origins as owner-operators, specialized expertise, and unique focus on providing actionable solutions for their clients provides a long runway to help fuel the next phase of its growth, including growing their highly-capable performance improvement solution set,” said Mario Masrieh, Managing Director at Trivest Partners.

Clearsight Advisors served as financial advisor and Chamberlain, Hrdlicka, White, Williams & Aughtry, P.C. as legal advisor to Applied Value. Jefferies served as financial advisor and Benesch, Friedlander, Coplan & Aronoff LLP as legal advisor to Trivest.

About Applied Value Group

Founded in 1997 by Executive Chairman Bruce Grant and the late Jan Stenbeck, Applied Value Group is a leading global management consulting firm with decades of experience growing and transforming organizations through hands-on value creation. With over 100 professionals, Applied Value Group provides a highly specialized and results-driven gross margin expansion, fixed cost reduction, and working capital efficiency services designed to accelerate growth and drive bottom-line improvements for its clients. Headquartered in New York, Applied Value Group also has offices in Miami, Stockholm, and Shanghai. Learn more at www.appliedvaluegroup.com.

About Trivest

Trivest Partners, headquartered in Miami with a presence in Charlotte, Chicago, Denver, Los Angeles, New York, and Toronto, is a private investment firm that focuses exclusively on the support and growth of founder-led and family-owned businesses in the U.S. and Canada, in both control and non-control transactions. Learn more at www.trivest.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250821073253/en/

Contacts

Media
Taylor Ingraham / Max Rayden
ASC Advisors
tingraham@ascadvisors.com / mrayden@ascadvisors.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye